Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL. It represents a heterogeneous malignancy concerning molecular alterations, morphology, clinical behavior, and treatment response. Due to the aggressive character of DLBCL, this lymphoid malignancy proliferates and tends to involve both nodal and extranodal sites, including the stomach, testis, and CNS; Relapse occurs in approximately 25–30% of DLBCL patients, with 10% exhibiting refractory disease. The majority of DLBCL relapses occur within two years of diagnosis. However, relapses after five years still happen in a fraction of DLBCL patients. They are linked to a favorable International Prognostic Index (IPI) score, limited-stage disease, and extranodal involvement at diagnosis. Survival rates have enhanced over the last several decades, with the most recent 5-year relative survival rate reported as 62.0% in the United States and 55.4% in Europe. More than 50% of patients with advanced-stage de novo DLBCL are cured with rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, depending on the number of adverse prognostic factors from the International Prognostic Score (IPI), 20% to 50% of patients with DLBCL will be refractory to R-CHOP or relapse after achieving complete response (CR).

 

Approximately 50 to 60% of patients with DLBCL achieve and maintain complete remission after first‑line therapy; 30 to 40% relapse and 10% have refractory disease.

DEL is more frequent among R/R DLBCL (45%) than primary DLBCL (20–35%) and is associated with inferior outcomes. Furthermore, DHITsig-positive cases are more common (60 percent) in diagnosis samples of relapsed DLBCL patients than non-relapsing patients (30 percent ).

 

The competitive landscape of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Yescarta®        Kite, a Gilead Company Phase 3

2          DPX-Survivac    ImmunoVaccine Technologies, Inc. (IMV Inc.)            Phase 2

3          bendamustine   Pharmatech      Phase 2

4          Axicabtagene Ciloleucel Gilead Sciences            Phase 2

5          ATG-010           Antengene Corporation  Phase 2

6          Loncastuximab Tesirine ADC Therapeutics S.A.  Phase 3

7          abexinostat       Xynomic Pharmaceuticals, Inc.  Phase 2

8          MEDI-551         MedImmune LLC           Phase 2

9          ALLO-501A       Allogene Therapeutics   Phase 2

10        Ibrutinib Pharmacyclics LLC.       Phase 2

Continued